

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Aquarius Surgical Technologies Inc. (the "Issuer").

Trading Symbol: ASTI

Number of Outstanding Listed Securities: 18,233,545

Date: January 8, 2017

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The responses from both the full page advertisements the Issuer took out in Urology Times, the nations' leading clinical journal for urologists, as well as the leads received from the targeted mailer campaign continued consistently throughout the month. Subsequent conversations, lunch and learn activities

and in-office presentations have led to several demonstrations and product evaluations across multiple states. Currently upcoming demonstrations and evaluations are scheduled for the states of Texas, Georgia, Florida, North and South Carolina, New York and Michigan.

Holmium laser deliveries have been slow but consistent over the month. The demand for this new laser has created a situation where sales demand is surpassing the current supply which is challenging the Issuer's ability to deliver and has created a short term backorder situation. With sales activity significantly higher than forecast, additional resources are being focused on expediting deliveries of the new holmium laser and the manufacturing facility has projected all backorders to be filled and consistent capacity to be maintained by the end of February 2018.

2. Provide a general overview and discussion of the activities of management.

As outlined in the Report on Business Section 1 above, sales of the Holmium Laser have exceeded management expectations. As a result, the Company has been seeking additional working capital to finance this demand.

The Company, being a new player in this space, has not as yet achieved normal financing terms from manufacturers, and until this changes the Company must internally finance inventory until credibility has been satisfactorily established.

Discussions continue with US Investment Bankers with a view toward developing a following in the Company progress in that market. This is an ongoing process

Finally, the Company continues to roll out its sales rep development program, subject to its financial constraints.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the

relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
None			

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

No current changes

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 8, 2018

N. Gary Van Nest
Name of Director or Senior
Officer

Signed "Gary Van Nest"
Signature
Acting CEO
Official Capacity

Issuer Details Name of Issuer Aquarius Surgical Technologies Inc.	For Month End Dec 2017	Date of Report YY/MM/D 18/01/8
Issuer Address 89 Scollard Street		
City/Province/Postal Code Toronto, ON M5R 1G4	Issuer Fax No. (902)484-7599	Issuer Telephone No. (902) 496-7594
Contact Name Gary Van Nest	Contact Position Acting CEO	Contact Telephone No (647) 308-0685.
Contact Email Address gary@sinaltainvestments.com	Web Site Address www.surgicallasersinc.com	